Efficacy and tolerability of 1.6% phenol-croton peeling vs. topical 5% imiquimod in the treatment of actinic cheilitis: a randomized controlled trial
| dc.contributor.author | Garbers, Luiz Eduardo Fabrício De Melo | |
| dc.contributor.author | Miola, Anna Carolina | |
| dc.contributor.author | Souza, Vinicius de | |
| dc.contributor.author | Brommonschenkel, Christina de Castro | |
| dc.contributor.author | Lima, Flavio de Oliveira | |
| dc.contributor.author | Minicucci, Eliana Maria | |
| dc.contributor.author | Miot, Helio Amante | |
| dc.contributor.institution | Universidade Estadual Paulista (UNESP) | pt |
| dc.date.accessioned | 2026-08-17T17:14:24Z | |
| dc.date.issued | 2024-11-21 | |
| dc.description.abstract | BACKGROUND: Trials evaluating the effectiveness of topical treatments for actinic cheilitis (AC) are scarce. Despite no comparative data, phenol-croton peeling has been reported as effective in treating this condition. OBJECTIVE: To assess for the treatment of AC the efficacy and tolerability of a single session of 1.6% phenol-croton peeling vs. topical 5% imiquimod cream applied for 30 days for the treatment of AC. METHODS: An open, randomized controlled trial was conducted to compare the effectiveness and tolerability of 1.6% phenol-croton peeling vs. topical 5% imiquimod for the treatment of AC [protocol registered at ReBEC (Brazilian Registry of Clinical Trials) - RBR-1044sz68]. Thirty-six patients with biopsy-proven AC were allocated into two groups (1 : 1): the imiquimod group received 5% topical imiquimod three times a week for 30 days, and the croton group underwent one session of 1.6% phenol-croton peeling. The primary outcome was the clearance of AC after 56 days. Secondary outcomes included clinical and histological parameters, adverse effects and clinical results after 180 days. RESULTS: Complete clinical clearance of AC (defined as clearance of both leukoplakia and hyperkeratosis) at day 56 and day 180 occurred in 17 of 18 (94%) participants from the croton group but in none of the 18 participants in the imiquimod group (P < 0.01). Improvement in all clinical parameters was more prominent in the croton group (P ≤ 0.01). Complete histological normalization at day 56 occurred in 72% of the croton group and only 17% in the imiquimod group (P < 0.01). Histological parameters such as atypia (keratinocyte intraepithelial neoplasia score), solar elastosis and hyperkeratosis reduced in intensity only in the croton group (P < 0.05). Adverse effects were most intense on day 7 in the croton group and persisted until day 21 in the imiquimod group. The study was prematurely terminated at the interim analysis. CONCLUSIONS: A single session of 1.6% phenol-croton peeling produced clinically and histologically superior results with a shorter recovery period compared with imiquimod for treating AC. | |
| dc.description.affiliation | Faculdade de Medicina de Botucatu, UNESP Medical School, Botucatu, SP, Brazil | |
| dc.description.affiliationUnesp | Faculdade de Medicina de Botucatu, UNESP Medical School, Botucatu, SP, Brazil | |
| dc.identifier | https://app.dimensions.ai/details/publication/pub.1182564358 | |
| dc.identifier.dimensions | pub.1182564358 | |
| dc.identifier.doi | 10.1093/ced/llae520 | |
| dc.identifier.issn | 0307-6938 | |
| dc.identifier.issn | 1365-2230 | |
| dc.identifier.orcid | 0000-0001-8848-3040 | |
| dc.identifier.orcid | 0000-0002-4664-6929 | |
| dc.identifier.orcid | 0000-0002-2596-9294 | |
| dc.identifier.pmid | 39570668 | |
| dc.identifier.uri | https://hdl.handle.net/11449/329755 | |
| dc.publisher | Oxford University Press (OUP) | |
| dc.relation.ispartof | Clinical and Experimental Dermatology; n. 4; v. 50; p. 826-835 | |
| dc.rights.accessRights | Acesso restrito | pt |
| dc.rights.sourceRights | closed | |
| dc.source | Dimensions | |
| dc.title | Efficacy and tolerability of 1.6% phenol-croton peeling vs. topical 5% imiquimod in the treatment of actinic cheilitis: a randomized controlled trial | |
| dc.type | Artigo | pt |
| dspace.entity.type | Publication | |
| relation.isOrgUnitOfPublication | a3cdb24b-db92-40d9-b3af-2eacecf9f2ba | |
| relation.isOrgUnitOfPublication.latestForDiscovery | a3cdb24b-db92-40d9-b3af-2eacecf9f2ba | |
| unesp.campus | Universidade Estadual Paulista (UNESP), Faculdade de Medicina, Botucatu | pt |

